Research has shown that third-generation assays produce results that are 50% – 60% lower in CKD patients, and 15% lower in non-CKD patients, when compared to second-generation assays.10,12 Third-generation assays are more specific to bioactive PTH than second-generation, and should in theory be more accurate in the evaluation of PTH status. The gene discussed is PTH; the disease is chronic kidney disease.